Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Sheward et al.,
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron),
bioRxiv, doi:10.1101/2021.12.19.473354 (Preprint) (In Vitro)
In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency.
4 In Vitro studies support the efficacy of bamlanivimab/etesevimab
[Liu, Sheward, VanBlargan, Zhou].
Sheward et al., 20 Dec 2021, preprint, 11 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2021.12.19.473354; this version posted December 20, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY 4.0 International license.
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Daniel J. Sheward1,2, Changil Kim1, Roy A. Ehling 3, Alec Pankow1, Xaquin Castro Dopico1,
Darren Martin2, Sai Reddy3, Joakim Dillner4, Gunilla B. Karlsson Hedestam1, Jan Albert 1,5,
Ben Murrell1
1
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South
Africa
3
Department of Biosystems Science and Engineering, ETH Zürich
4
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
5
Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
2
Abstract
The recently-emerged SARS-CoV-2 B.1.1.529 variant (Omicron) is spreading rapidly in many
countries, with a spike that is highly diverged from the pandemic founder, raising fears that it
may evade neutralizing antibody responses. We cloned the Omicron spike from a diagnostic
sample which allowed us to rapidly establish an Omicron pseudotyped virus neutralization
assay, sharing initial neutralization results only 13 days after the variant was first reported to the
WHO, 8 days after receiving the sample.
Here we show that Omicron is substantially resistant to neutralization by several monoclonal
antibodies that form part of clinical cocktails. Further, we find neutralizing antibody responses in
pooled reference sera sampled shortly after infection or vaccination are substantially less potent
against Omicron, with neutralizing antibody titers reduced by up to 45 fold compared to those for
the pandemic founder. Similarly, in a cohort of convalescent sera prior to vaccination,
neutralization of Omicron was low to undetectable. However, in recent samples from two cohorts
from Stockholm, Sweden, antibody responses capable of cross-neutralizing Omicron were
prevalent. Sera from infected-then-vaccinated healthcare workers exhibited robust
cross-neutralization of Omicron, with an average potency reduction of only 5-fold relative to the
pandemic founder variant, and some donors showing no loss at all. A similar pattern was
observed in randomly sampled recent blood donors, with an average 7-fold loss of potency.
Both cohorts showed substantial between-donor heterogeneity in their ability to neutralize
Omicron. Together, these data highlight the extensive but incomplete evasion of neutralizing
antibody responses by the Omicron variant, and suggest that increasing the magnitude of
neutralizing antibody responses by boosting with unmodified vaccines may suffice to raise titers
to levels that are protective.
sheward
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit